epoetin alfa
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Stomach Neoplasms
Conditions
Stomach Neoplasms, Rectal Neoplasms
Trial Timeline
Dec 1, 2001 → Dec 1, 2003
NCT ID
NCT00036400About epoetin alfa
epoetin alfa is a phase 3 stage product being developed by Johnson & Johnson for Stomach Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00036400. Target conditions include Stomach Neoplasms, Rectal Neoplasms.
What happened to similar drugs?
1 of 7 similar drugs in Stomach Neoplasms were approved
Approved (1) Terminated (1) Active (5)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00270010 | Phase 2 | Completed |
| NCT00266617 | Phase 2 | Completed |
| NCT00002022 | Pre-clinical | Completed |
| NCT00269984 | Phase 2 | Completed |
| NCT00269945 | Phase 2 | Completed |
| NCT00270114 | Phase 2/3 | Completed |
| NCT00446602 | Phase 2 | Withdrawn |
| NCT00270179 | Phase 3 | Completed |
| NCT00269997 | Phase 2 | Completed |
| NCT00270023 | Phase 2/3 | Completed |
| NCT00270270 | Phase 2 | Completed |
| NCT00337935 | Phase 2 | Completed |
| NCT00306267 | Phase 2 | Terminated |
| NCT00641589 | Phase 1 | Completed |
| NCT00246298 | Phase 2 | Terminated |
| NCT00212875 | Phase 2 | Completed |
| NCT00236405 | Phase 2 | Terminated |
| NCT00240734 | Phase 2 | Terminated |
| NCT00210587 | Phase 3 | Completed |
| NCT00236678 | Phase 2 | Terminated |
Competing Products
20 competing products in Stomach Neoplasms